- Home
- ARL vs LYEL Comparison
ARL vs LYEL Comparison
Compare ARL & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARL | LYEL |
|---|---|---|
| Founded | 1999 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 245.7M | 681.3M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | ARL | LYEL |
|---|---|---|
| Price | $16.28 | $33.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 1.5K | ★ 64.7K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $49,060,000.00 | $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $45.62 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.43 | $7.65 |
| 52 Week High | $17.00 | $35.16 |
Technical Indicators
Market Signals| Indicator | ARL | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 56.50 | 72.79 |
| Support Level | $15.45 | $32.00 |
| Resistance Level | $16.60 | $34.78 |
| Average True Range (ATR) | 0.38 | 2.48 |
| MACD | 0.11 | 0.33 |
| Stochastic Oscillator | 75.29 | 84.59 |
Price Performance
Historical ComparisonAbout ARL American Realty Investors Inc.
American Realty Investors Inc is a fully integrated externally managed real estate company. The company operates high-quality multifamily and commercial properties throughout the Southern United States and also invests in mortgage notes receivable and in land that is either held for appreciation or development. It operates in two reportable segments; the acquisition, development, ownership and management of multifamily properties (Residential); and the acquisition, development, ownership, and management of commercial properties (Commercial), which predominantly comprise office properties. Maximum revenue is generated from its Residential segment, which includes the rental of apartments and other tenants.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.